Amgen & Novartis expand collaboration for migraine drug Erenumab

Amgen has expanded commercial collaboration with Novartis for erenumab, which is being investigated for the prevention of migraine. This expanded commercial collaboration builds on a global neuroscience collaboration in Alzheimer’s disease and migraine established in 2015 between Novartis and Amgen. This expanded collaboration leverages Novartis’ strong and established presence in neuroscience to more effectively reach people with migraine. The companies have agreed to combine capabilities to co-commercialise erenumab in the US. Amgen retains exclusive commercialisation rights in Japan. Novartis gains exclusive rights to commercialise erenumab in Canada, and retains its existing commercialisation rights in rest of the world. The companies